Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $596 | In Stock | |
10 mg | $959 | In Stock | |
25 mg | $1,420 | In Stock | |
50 mg | $1,920 | In Stock | |
100 mg | $2,590 | In Stock |
Description | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma. |
In vitro | In vitro, vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into a bispecific anti-human CD70/KWAR23 antibody. The results show that KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1]. |
In vivo | In SRG mice, vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits the growth of Burkitt’s lymphoma cells[1]. |
Alias | SGN-70 |
Molecular Weight | 146.1 kDa |
Cas No. | 1165740-62-4 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.